Publication: PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
Date
Date
Date
Citations
Moraes Ribeiro, E., Secker, K.-A., Nitulescu, A.-M., Schairer, R., Keppeler, H., Wesle, A., Schmid, H., Schmitt, A., Neuber, B., Chmiest, D., Podavini, S., Märklin, M., Klimovich, B., Schmitt, M., Korkmaz, F., Lengerke, C., Schneidawind, C., & Schneidawind, D. (2024). PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Journal for ImmunoTherapy of Cancer, 12(1), e007829. https://doi.org/10.1136/jitc-2023-007829
Abstract
Abstract
Abstract
BACKGROUND
Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent acute and chronic GVHD. In addition, iNKT cells are crucial for efficient immune responses against malignancies and contribute to reduced relapse rates after transplantation. Chimeric antigen receptors (CAR) redirect effector cells to cell surface antigens and enhance killing of target cel
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Moraes Ribeiro, E., Secker, K.-A., Nitulescu, A.-M., Schairer, R., Keppeler, H., Wesle, A., Schmid, H., Schmitt, A., Neuber, B., Chmiest, D., Podavini, S., Märklin, M., Klimovich, B., Schmitt, M., Korkmaz, F., Lengerke, C., Schneidawind, C., & Schneidawind, D. (2024). PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity. Journal for ImmunoTherapy of Cancer, 12(1), e007829. https://doi.org/10.1136/jitc-2023-007829